AstraZeneca on course to roll out jab for new variants by autumn

UK

AstraZeneca has said it is on course to roll out a coronavirus vaccine that is effective against new variants by the autumn.

The company, which has produced a COVID-19 vaccine alongside University of Oxford, said clinical trials for the next generation of jab would commence in the spring.

It added that the plan would be to go into mass production in six to nine months.

Speaking as he unveiled AstraZeneca’s annual results, chief executive Pascal Soriot said there should be a drop in hospital admissions “very soon” as a consequence of the UK’s vaccine rollout.

AstraZeneca is set to deliver 100 million doses of its current vaccine around the world this month, doubling to 200 million a month by April.

Mr Soriot said: “100 million doses in February means 100 million vaccinations, which means hundreds of thousands of severe infections avoided and it also means thousands of deaths that are avoided.”

“We’re going to save thousands of lives and that’s why we come to work every day as individuals,” he added.

“Is it perfect? No it’s not perfect, but it’s great. Who else is making 100 million doses in February?” Mr Soriot said on a conference call about the vaccine.

Products You May Like

Articles You May Like

‘I loved her’: Cheers co-stars pay tribute to ‘unique and wonderful’ Kirstie Alley
England cruise past Senegal to set up quarter-final clash with World Cup holders France
Army may be deployed to ease possible strike disruption over Christmas
‘They were going to find a way to destroy me’: Harry and Meghan’s bombshell documentary airs
Strep A deaths in children rise to 15 across UK

Leave a Reply

Your email address will not be published. Required fields are marked *